Pegasus interferon alpha is a brand name for peginterferon alfa-2a, a medication used to treat certain types of viral infections and cancers. It is a form of interferon alfa-2a that has been modified with polyethylene glycol, which extends its duration of action in the body [1].
What is Pegasus Interferon Alpha Used For?
Pegasus interferon alpha (peginterferon alfa-2a) is prescribed for the treatment of chronic hepatitis C, chronic hepatitis B, and certain types of leukemia, including hairy cell leukemia and chronic myeloid leukemia [1][2]. It is often used in combination with other antiviral medications for hepatitis C [3].
How Does Pegasus Interferon Alpha Work?
Interferons are naturally occurring proteins in the body that help the immune system fight off infections and abnormal cells. Peginterferon alfa-2a works by stimulating the immune system to attack the hepatitis C virus or cancerous cells. The pegylation process makes the drug last longer in the bloodstream, allowing for less frequent dosing compared to non-pegylated interferons [1][4].
When Does Patent Protection for Pegasus Interferon Alpha Expire?
Drug patent expiration dates are complex and can involve multiple patents covering different aspects of a drug, such as the active ingredient, formulation, or method of use. Information on specific patent expiry dates for pegylated interferon alfa-2a and related formulations can be found on specialized patent databases [5].
Who Makes Pegasus Interferon Alpha?
Pegylated interferon alfa-2a was developed by Roche and is marketed under the brand name Pegasys [1].
What Are the Side Effects of Pegasus Interferon Alpha?
Common side effects associated with pegylated interferon alfa-2a include flu-like symptoms such as fever, chills, headache, muscle aches, and fatigue. Other potential side effects can include mood changes, depression, difficulty sleeping, nausea, diarrhea, hair thinning, and changes in blood counts [1][2]. Patients experiencing significant side effects should consult their healthcare provider.